Want to see MOLN full AI Analyst Report?
MOLN Stock Chart & Stats
$4.20
-$0.03(-0.55%)
At close: 4:00 PM EST
$4.20
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$3.41 - $5.36
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.31K
Market Cap
$158.53M
Enterprise Value$41.99M
Total Cash (Recent Filing)$78.53M
Total Debt (Recent Filing)$3.33M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 25, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-32.29
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$12.50Price Target Upside197.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$13.94M
Bulls Say, Bears Say
Bulls Say
Proprietary DARPin PlatformMolecular Partners' DARPin platform is a durable competitive asset: modular, multi-specific protein engineering enables differentiated therapeutic formats across oncology and radiotherapeutics. A platform strategy supports repeated pipeline generation, partner licensing, and long-term value creation independent of single assets.
Broad, Advancing Clinical PipelineThe company runs multiple clinical programs (Radio-DARPin MP0712/MP0726, MP0317, MP0533) with ongoing dose escalation and planned readouts. Diversified modalities and indications reduce single-asset binary risk and increase durable upside from several clinical catalysts across 2-3 years.
Low Leverage And Multi-year Cash RunwayModest debt (debt/equity ~0.05) plus a reported CHF93.1M cash position provides structural funding to execute multiple clinical programs into 2028. Low leverage reduces refinancing pressure and gives management time to reach de-risking data before material external financing is required.
Bears Say
No Recent Product Revenue; Large Net LossesThe absence of recurring product revenues and sustained multi-year losses mean the business cannot self-fund development. Persistent unprofitability increases reliance on external capital, raising long-term dilution risk and limiting reinvestment flexibility if clinical timelines slip.
Sustained Operating Cash BurnSubstantial negative operating and free cash flow indicates ongoing consumption of cash to fund R&D. Worsening FCF growth reduces optionality: even with current reserves, consistent burn increases the probability and size of future fundraising rounds, pressuring strategic autonomy.
Eroded Equity Base From Past Gains/lossesMaterial erosion of shareholders' equity weakens the balance-sheet buffer against setbacks and reduces collateral for partnerships or debt. A smaller equity base makes future financing more dilutive and constrains the company's ability to pursue large, expensive late-stage trials or M&A without significant external capital.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.41 and its highest was $5.36 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $158.53M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Aug 25, 2026 which is in 56 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Mar 12, 2026. The company reported -$0.435 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.035.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.44.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.435 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -10.403%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$12.50
▲(197.62% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.89% Other Institutional Investors
91.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---